一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Asian Journal of Pharmaceutical Sciences >>article
Asian Journal of Pharmaceutical Sciences

Asian Journal of Pharmaceutical Sciences

IF: 11.9
Download PDF

Optimize the combination regimen of Trastuzumab and Nab-paclitaxel in HER2-positive tumors via modulating Caveolin-1 expression by lovastatin

Published:1 August 2022 DOI: 10.1016/j.ajps.2022.06.002 PMID: 36382307
Canyu Yang , Shumin Fan , Xing Wang , Wei Liu , Long Yang , Bing He , Wenbing Dai , Hua Zhang , Xueqing Wang , Qiang Zhang

Abstract

The combination regimen of trastuzumab (Tras) plus Nab-paclitaxel (Nab) is recommended to treat HER2-positive (HER2+) cancers. However, they exert effects in different mechanisms: Tras need to stay on cell membranes, while Nab need to be endocytosed, therefore the concurrent combination regimen may not be the best one in HER2+ tumors treatment. Caveolin-1 (Cav-1) is a key player in mediating their endocytosis and is associated with their efficacy, but few researches noticed the opposite effect of Cav-1 expression on the combination efficacy. Herein, we systematically studied the Cav-1 expression level on the combination efficacy and proposed an optimized and clinically feasible combination regimen for HER2+ Cav-1High tumor treatment. In the regimen, lovastatin (Lova) was introduced to modulate the Cav-1 expression and the results indicated that Lova could downregulate Cav-1 expression, increase Tras retention on cell membrane and enhance the in vitro cytotoxicity of Tras in HER2+ Cav-1High cells but not in HER2+ Cav-1Low cells. Therefore, by exchanging the dosing sequence of Nab and Tras, and by adding Lova at appropriate time points, the precise three-drug-sequential regimen (PTDS, Nab(D1)-Lova(D2)-Lova & Tras(D2+12?h)) was established. Compared with the concurrent regimen, the PTDS regimen exhibited a higher in vitro cytotoxicity and a stronger tumor growth inhibition in HER2+ Cav-1High tumors, which might be a promising combination regimen for these patients in clinics.

Substances (8)

Materials
Procduct Name CAS Molecular Formula Supplier Price
Lovastatin 75330-75-5 C24H36O5 707 suppliers $8.00-$1208.70
Lovastatin 75330-75-5 C24H36O5 707 suppliers $8.00-$1208.70
Lovastatin 75330-75-5 C24H36O5 707 suppliers $8.00-$1208.70
Lovastatin 75330-75-5 C24H36O5 707 suppliers $8.00-$1208.70
SiMvastatin EP IMpurity E 75330-75-5 - Inquiry
SiMvastatin EP IMpurity E 75330-75-5 - Inquiry
LOVASTATIN 75330-75-5 - Inquiry
LOVASTATIN 75330-75-5 - Inquiry

Similar articles

IF:9.1

Antagonising Yin Yang 1 ameliorates the symptoms of lupus nephritis via modulating T lymphocyte signaling

Pharmacological research Haoxing Yuan, Zheng Peng,etc Published: 1 December 2024
IF:2.6

Ammonium lauryl sulfate-induced apoptotic cell death may be due to mitochondrial dysfunction triggered by caveolin-1

Toxicology in Vitro Eun-Jung Park , Eunsol Seong ,etc Published: 1 June 2019
IF:0.9

Nanoparticle Albumin-Bound Paclitaxel is More Effective Than Paclitaxel in Experimental Endometrial Cancer

Science of Advanced Materials Jing Huang,?Hongqi Huo,etc Published: 1 May 2022
沈阳市| 涡阳县| 宝兴县| 奉新县| 云安县| 花莲市| 乌兰浩特市| 崇仁县| 新丰县| 九江县| 阳新县| 民县| 临高县| 墨竹工卡县| 武乡县| 寻甸| 柞水县| 司法| 青铜峡市| 桃园市| 沙田区| 鄂尔多斯市| 海兴县| 墨玉县| 滨海县| 五河县| 方山县| 景洪市| 济源市| 改则县| 舞阳县| 苍山县| 洛南县| 犍为县| 辛集市| 社会| 揭阳市| 维西| 石景山区| 武乡县| 德钦县|